gsk rsv：RSV 疫苗戰漸趨白熱化，上市核准新進展一次看
RSV 疫苗戰漸趨白熱化，上市核准新進展一次看
Arexvy Respiratory Syncytial Virus 欣剋融呼吸道融合病毒疫苗
https://tw.gsk.com
產品中文名稱：欣剋融呼吸道融合病毒疫苗; 產品英文名稱：Arexvy Respiratory Syncytial Virus Vaccine; 產品主成分：RSVPreF3 antigen.
脫穎而出，GSK 旗下RSV 疫苗率先獲美國FDA 核准！
https://geneonline.news
在試驗中，疫苗對於60 歲以上成人的RSV-LRTD 抵抗率整體效能達到82.6％，滿足主要療效指標。對於嚴重的RSV-LRTD（定義為影響日常活動的發作）有效性更高達94.1% ...
US FDA approves expanded age indication for GSK's ...
https://www.gsk.com
In May 2023, the FDA approved GSK's RSV vaccine for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial ...
GSK搶頭香！首款RSV成人疫苗Arexvy獲准
https://ibmi.taiwan-healthcare
這是美國有史以來首個被批准的RSV疫苗。GSK與輝瑞分別於去年11月、12月先後取得FDA優先審查資格，預計將在本月底對輝瑞的候選產品作出最終審查決定。
GSK RSVPreF3 Vaccine (AREXVY)
https://www.cdc.gov
A systematic review of evidence on the efficacy and safety of GSK RSVPreF3 vaccine among persons aged 60 years and older was conducted.
RSV Vaccine
https://arexvy.com
AREXVY is an FDA-approved vaccine for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus in people 60 years of age ...
US FDA approves GSK's Arexvy
https://www.gsk.com
Ground-breaking approval enables adults aged 60 years and older to be protected from RSV disease for the first time.
GSK RSV Vaccine Summary
https://www.cdc.gov
Presentations and Indications. AREXVY is a vaccine indicated for active immunization for the prevention of lower respiratory tract disease ...
GSK's RSV vaccine
https://www.gsk.com
The FDA has approved GSK's RSV vaccine for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) ...